FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3096677891> ?p ?o ?g. }

• W3096677891 endingPage "6" @default.
• W3096677891 startingPage "5" @default.
• W3096677891 abstract "Background: Multiple myeloma (MM) is a plasma cell disorder and demonstrates overexpression of B cell maturation antigen (BCMA). Our objective is to evaluate the safety and efficacy of chimeric antigen receptor T cells (CAR-T) against BCMA in patients with relapsed/refractory multiple myeloma (RRMM). Methods: We conducted a systematic literature search using PubMed, Cochrane, Clinicaltrials.gov, and Embase databases. We also searched for data from society meetings. A total of 935 articles were identified, and 610 were screened for relevance. Results: Data from thirty-one original studies with a total of 871 patients (pts) were included based on defined eligibility criteria, see Table 1. Hu et al. reported an overall response rate (ORR) of 100% in 33 pts treated with BCMA CAR-T cells including 21 complete response (CR), 7 very good partial response (VGPR), 4 partial response (PR). Moreover, 32 pts achieved minimal residual disease (MRD) negative status. Chen et al. reported ORR of 88%, 14% CR, 6% VGPR, and 82% MRD negative status with BCMA CAR-T therapy in 17 RRMM pts. In another clinical trial by Han et al. BCMA CAR-T therapy demonstrated an ORR of 100% among 7 evaluable pts with 43% pts having ≥ CR and 14% VGPR. An ORR of 100% with 64% stringent CR (sCR) and 36% VGPR was reported with novel anti-BCMA CART cells (CT103A). Similarly, Li et al. reported ORR of 87.5%, sCR of 50%, VGPR 12.5%, and PR 25% in 16 pts. BCMA targeting agent, JNJ-4528, showed ORR of 91%, including 4sCR, 2CR, 10MRD, and 7VGPR. CAR-T- bb2121 demonstrated ORR of 85%, sCR 36%, CR 9%, VGPR 57%, and MRD negativity of 100% (among 16 responsive pts). GSK2857916, a BCMA targeting CAR-T cells yielded ORR of 60% in both clinical trials. Three studies utilizing bispecific CART cells targeting both BCMA & CD38 (LCARB38M) reported by Zhao et al., Wang et al., and Fan et al. showed ORR of 88%, 88%, & 100% respectively. Topp et al. reported ORR of 31% along with 5 ≥CR and 5 MRD negative status in 42 pts treated with Bi T-cells Engager BiTE® Ab BCMA targeting antigen (AMG420). One clinical trial presented AUTO2 CART cells therapy against BCMA with an ORR of 43%, VGPR of 14%, and PR of 28%. CT053CAR-BCMA showed 14sCR and 5CR with a collective ORR of 87.5% and MRD negative status of 85% in 24 and 20 evaluable pts, respectively. Likewise, Mikkilineni et al. reported an ORR of 83%, sCR of 16.7%, and VGPR & PR of 25% and 41% in 12 pts treated with FHVH-BCMA T cells. Similar results are also reported in other clinical trials of BCMA targeting CART therapy (Table 1). The most common adverse effects exhibited were grade 1-3 hematologic (cytopenia) and cytokine release syndrome (CRS) (mostly reversible with tocilizumab). Conclusion: Initial data from ongoing clinical trials using BCMA targeting CAR-T therapy have yielded promising results both in terms of improved outcome and tolerable toxicity profiles. Although two phase 3 trails are ongoing, additional data is warranted to further ensure the safety and efficacy of anti-BCMA CAR-T cells therapy in pts with RRMM for future use. Disclosures Anwer: Incyte, Seattle Genetics, Acetylon Pharmaceuticals, AbbVie Pharma, Astellas Pharma, Celegene, Millennium Pharmaceuticals.: Honoraria, Research Funding, Speakers Bureau." @default.
• W3096677891 created "2020-11-09" @default.
• W3096677891 creator A5005278836 @default.
• W3096677891 creator A5005991606 @default.
• W3096677891 creator A5006668401 @default.
• W3096677891 creator A5008400959 @default.
• W3096677891 creator A5009769468 @default.
• W3096677891 creator A5030748998 @default.
• W3096677891 creator A5032489256 @default.
• W3096677891 creator A5042413564 @default.
• W3096677891 creator A5043261871 @default.
• W3096677891 creator A5046499407 @default.
• W3096677891 creator A5058548627 @default.
• W3096677891 creator A5073268835 @default.
• W3096677891 creator A5075467286 @default.
• W3096677891 creator A5087005055 @default.
• W3096677891 date "2020-11-05" @default.
• W3096677891 modified "2023-09-27" @default.
• W3096677891 title "Safety and Efficacy of Anti-Bcma CAR-T Cells for Relapsed/Refractory Multiple Myeloma: A Systematic Review of Literature" @default.
• W3096677891 doi "https://doi.org/10.1182/blood-2020-134529" @default.
• W3096677891 hasPublicationYear "2020" @default.
• W3096677891 type Work @default.
• W3096677891 sameAs 3096677891 @default.
• W3096677891 citedByCount "1" @default.
• W3096677891 countsByYear W30966778912021 @default.
• W3096677891 crossrefType "journal-article" @default.
• W3096677891 hasAuthorship W3096677891A5005278836 @default.
• W3096677891 hasAuthorship W3096677891A5005991606 @default.
• W3096677891 hasAuthorship W3096677891A5006668401 @default.
• W3096677891 hasAuthorship W3096677891A5008400959 @default.
• W3096677891 hasAuthorship W3096677891A5009769468 @default.
• W3096677891 hasAuthorship W3096677891A5030748998 @default.
• W3096677891 hasAuthorship W3096677891A5032489256 @default.
• W3096677891 hasAuthorship W3096677891A5042413564 @default.
• W3096677891 hasAuthorship W3096677891A5043261871 @default.
• W3096677891 hasAuthorship W3096677891A5046499407 @default.
• W3096677891 hasAuthorship W3096677891A5058548627 @default.
• W3096677891 hasAuthorship W3096677891A5073268835 @default.
• W3096677891 hasAuthorship W3096677891A5075467286 @default.
• W3096677891 hasAuthorship W3096677891A5087005055 @default.
• W3096677891 hasBestOaLocation W30966778911 @default.
• W3096677891 hasConcept C121332964 @default.
• W3096677891 hasConcept C126322002 @default.
• W3096677891 hasConcept C141071460 @default.
• W3096677891 hasConcept C142424586 @default.
• W3096677891 hasConcept C143998085 @default.
• W3096677891 hasConcept C2776364478 @default.
• W3096677891 hasConcept C71924100 @default.
• W3096677891 hasConcept C87355193 @default.
• W3096677891 hasConcept C90924648 @default.
• W3096677891 hasConceptScore W3096677891C121332964 @default.
• W3096677891 hasConceptScore W3096677891C126322002 @default.
• W3096677891 hasConceptScore W3096677891C141071460 @default.
• W3096677891 hasConceptScore W3096677891C142424586 @default.
• W3096677891 hasConceptScore W3096677891C143998085 @default.
• W3096677891 hasConceptScore W3096677891C2776364478 @default.
• W3096677891 hasConceptScore W3096677891C71924100 @default.
• W3096677891 hasConceptScore W3096677891C87355193 @default.
• W3096677891 hasConceptScore W3096677891C90924648 @default.
• W3096677891 hasIssue "Supplement 1" @default.
• W3096677891 hasLocation W30966778911 @default.
• W3096677891 hasOpenAccess W3096677891 @default.
• W3096677891 hasPrimaryLocation W30966778911 @default.
• W3096677891 hasRelatedWork W2002120878 @default.
• W3096677891 hasRelatedWork W2003938723 @default.
• W3096677891 hasRelatedWork W2047967234 @default.
• W3096677891 hasRelatedWork W2118496982 @default.
• W3096677891 hasRelatedWork W2351796763 @default.
• W3096677891 hasRelatedWork W2435227317 @default.
• W3096677891 hasRelatedWork W2439875401 @default.
• W3096677891 hasRelatedWork W2528057197 @default.
• W3096677891 hasRelatedWork W4238867864 @default.
• W3096677891 hasRelatedWork W2525756941 @default.
• W3096677891 hasVolume "136" @default.
• W3096677891 isParatext "false" @default.
• W3096677891 isRetracted "false" @default.
• W3096677891 magId "3096677891" @default.
• W3096677891 workType "article" @default.